Results 171 to 180 of about 1,929,926 (305)

Efficacy and Safety of Abatacept Versus Placebo During Peanut Oral Immunotherapy for Adults With Severe Peanut Allergy

open access: yesAllergy, EarlyView.
In this Phase 2a trial, severely peanut‐allergic participants were randomized to abatacept versus placebo with peanut oral immunotherapy (OIT) for 24 weeks, followed by 12 weeks of OIT alone. No significant difference was observed for the primary efficacy outcome (the relative change from baseline in peanut‐specific/total IgE ratio at 24 weeks), but ...
Marie‐Lee Simard   +12 more
wiley   +1 more source

An Extended Transcriptomic Landscape of Human Skin Mast Cells: Unveiling Lineage‐Specific Noncoding RNA Dynamics in FcεRI Activation

open access: yesAllergy, EarlyView.
FcεRI cross‐linking triggers widespread transcriptional reprogramming in human skin mast cells (> 5000 genes, > 6400 promoters, and 48 novel mast cell‐enriched lncRNAs). Breast skin and foreskin mast cells share core transcriptional programs but differ selectively in tryptase isoenzymes and IL‐8/IL‐1RA release.
Gürkan Bal   +12 more
wiley   +1 more source

Comparing contact dermatitis due to tissue adhesives in port-site closure. [PDF]

open access: yesSurg Endosc
Holihan JL   +8 more
europepmc   +1 more source

Corticosteroid Exposure in Autoimmune Hepatitis: Early Toxicity, Cumulative Burden and Associations With Long‐Term Patient‐Reported Outcomes

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
In a patient‐reported cohort of 565 adults with autoimmune hepatitis, 96.6% reported corticosteroid‐related side effects within 6 months and long‐term toxicity increased with cumulative exposure. The findings support earlier tapering, toxicity monitoring, lower induction dosing when appropriate and selective budesonide use in carefully chosen non ...
Elizabeth Gentry   +4 more
wiley   +1 more source

Contact dermatitis.

open access: yesNagoya journal of medical science, 2000
openaire   +2 more sources

Cancer pain: current practice and emerging targets

open access: yesBritish Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye   +5 more
wiley   +1 more source

Peripheral targets for neuropathic pain

open access: yesBritish Journal of Pharmacology, EarlyView.
Neuropathic pain represents a significant clinical challenge, with still limited pharmacological approaches to symptomatic relief. This review focuses on molecular targets implicated in neuropathic pain, particularly those involved in peripheral mechanisms. Using the IUPHAR/BPS database of biological targets, their occurrence together with ‘neuropathic
Amirhossein Afsharipour   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy